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Abstract
Background: Docetaxel is a chemotherapeutic agent of the taxane class of drugs for the treatment of breast
cancer. We present a female patient who noted decreased vision after docetaxel treatment.
Case presentation: A 45-year-old female patient received docetaxel treatment after resection of a breast carcinoma.
Funduscopy and optical coherence tomography (OCT) showed cystoid macular edema on both eyes. Dilated
funduscopy also showed bone spicule-like pigmented deposits, typical for retinitis pigmentosa. Besides the
fundus appearance restricted peripheral vision and scotopic electroretinogram confirmed the diagnosis of retinitis
pigmentosa. Chemotherapy was discontinued following a consulation with the oncologist of the patient. After five
weeks, visual acuity improved significantly along with decrease of retinal thickness measured by OCT.
Conclusion: Docetaxel may cause ocular adverse effects such as cystoid macular edema. Ophthalmological
examination is warranted for patients with visual complaints during docetaxel chemotherapy.
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Background
Docetaxel belongs to taxane class of drugs, which are
anti-mitotic chemotherapeutical agents registered for the
treatment of various types of solid tumors including
breast cancer [1].
Retinitis pigmentosa (RP) is an inherited retinal dys-
trophy causing progressive visual field constriction. RP
initially affects midperipheral photoreceptors, then as
the disease progresses more central retinal regions become
affected. Typically, structural changes such as decrease of
the foveal thickness and retinal pigment epithelium
atrophy and functional changes on full-field and multi-
focal electroretinogram (ERG) are associated with RP
[2,3]. Cystoid macular edema (CME) can be detected in
10–20% of RP patients [4].
We present a female patient who noted decreased vi-
sion after docetaxel treatment.
Case presentation
A 45-year-old Caucasian woman received docetaxel-
doxorubicin-cyclophosphamide chemotherapy after sur-
gical resection of an invasive ductal breast carcinoma in
clinical stage IIb.
According to the medical history of the patient, she
had no pre-existing ocular diseases, and based on her
statement her ocular symptoms started following the be-
ginning of the treatment. She presented at our depart-
ment 12 weeks after initiation of chemotherapy. By that
time she already received 4 series of TAC treatment (do-
cetaxel 75 mg/m2, doxorubicin 50 mg/m2 and cyclo-
phosphamide 500 mg/m2 q3w).
Her best corrected visual acuity (BCVA) was 0.3 and
0.2. Anterior segments showed no pathologies, intraocu-
lar pressure was normal.
Dilated fundus examination revealed cystoid macular
edema (CME) around the fovea on both eyes (Figure 1),
which was also confirmed by optical coherence tomog-
raphy (OCT) (Figure 2A and B). Large cystic spaces were
observed in the outer nuclear layer and small cystic spaces
in the inner nuclear layer on both eyes. Photoreceptor
inner/outer segment (IS/OS) junction was discontinuous
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but relatively intact underneath the fovea and absent out-
side this area. Retinal thickness was increased in the cen-
ter of the macula according to the edema and subnormal
outside the perifoveal area. There was no evidence of
vitreo-retinal interface, retinal pigment epithelium (RPE)
or sub-RPE abnormalities on the images.
Additionally, as an unexpected finding bone spicule-
like pigmented deposits could be seen at the periphery,
characteristic for retinitis pigmentosa (RP) (Figure 1).
Scotopic electroretinogram was almost completely extin-
guished and visual field showed concentric constriction
to 5° on both eyes, confirming the presumed diagnosis.
Fluorescein angiography probably would not have had
an effect on differential diagnosis as no leakage was ex-
pected based on the literature of CME induced by either
RP or taxane-based chemotherapy [5-7]. Kuznetcova et al.
[7] suggest that the mechanisms of developing CME by
certain etiologies, e.g. inflammatory diseases and taxane
treatment may be different. In CME cases induced by in-
flammation the tight junctions are affected and they be-
come potential leaking points. Taxane treatment causes
dysfunction in the cytoskeleton of the retinal pigment
epithelium, the choroid - pigment epithelium border is
unaffected and therefore leakage is not to be expected. Be-
sides lacking differential diagnostic value, results of the
angiography would not have had any therapeutic conse-
quences either. Taking these facts to consideration and
judging the general clinical state of the patient fluorescein
angiography was not performed.
At this point, following a consultation with the pa-
tient’s oncologist and detailed discussion with the pa-
tient, chemotherapy was stopped. Five weeks after
the discontinuation of chemotherapy and additional
topical nepafenac treatment the visual acuity of the
patient improved significantly. After 4 months of
follow-up BCVA was 1.0 on both eyes. Retinal thick-
ness in the perifoveal area also decreased gradually
with the resolution of intraretinal cysts on OCT
scans (Figure 2G and H). Visual acuity and retinal
thickness remained stable after discontinuation of the
topical therapy.
Discussion
Our patient presented with bilateral CME and RP after
receiving docetaxel-doxorubicin-cyclophosphamide treat-
ment. The most likely explanation for these conditions is
that CME was a chemotherapy side-effect while RP was
an undetected pre-existing disease. This association is also
supported by the reversibility of CME after discontinu-
ation of chemotherapy. Taxane-based chemotherapy may
induce CME as reported by more than a dozen case stud-
ies in the past decade [5,6,8-11]. The majority of these
studies concern paclitaxel treatment. There are only two
case studies that report findings on a CME after docetaxel
treatment. In the first Teitelbaum and coworkers [6] de-
scribe a CME with normal fluorescein angiography diag-
nosed by fundoscopy, in the second by Telander et al. [11]
diagnosis is backed by OCT evidence. There are no re-
ports so far in the literature of a co-occurrence of RP and
docetaxel induced CME. According to papers dealing with
CME induced by paclitaxel, outer retinal layers seem to be
more affected [12]. However, both docetaxel treatment
and RP associated CME are reported to involve inner and
outer layers [7,13], this is also the case with our patient.
Figure 1 Composit fundus photography. Bone spicule-like pigmented deposits at the mid-periphery and cystoid macular edema at the fovea
symmetrically on both sides.
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To our knowledge, no cases are reported that CME
may be caused by cyclophosphamide or doxorubicin
treatment, however the combination of cyclophospha-
mide and paclitaxel was reported in one CME case
[5].
There are three alternative hypotheses: First, based
on our observations, it is possible that docetaxel treat-
ment may trigger the progression of a pre-existing RP
and also increase the likelihood for CME to develop.
Chaudhry et al. reported that in patients treated with
chemotherapy, neuropathy may develop early or exist-
ing neuropathy may get worse in cases of pre-existing
neuropathology, e.g. diabetes mellitus [14]. According
to this study, in our case RP could have acted as a pre-
existing neuropathology and chemotherapy as a trigger
that caused the disease to progress to be symptomatic.
Figure 2 OCT scans of the macula of both eyes after 4 series of TAC treatment (A, B). Large cystic spaces are present in the outer nuclear
layer and small cystic spaces in the inner nuclear layer. Photoreceptor inner/outer segment (IS/OS) junction is discontinuous but relatively intact
underneath the fovea and absent outside this area. Retinal thickness is lower outside the perifoveal area. Scans 5 weeks (C, D), 8 weeks (E, F),
12 weeks (G, H) and 17 weeks (I, J) after discontinuation of the chemotherapy. Retinal thickness in the perifoveal area gradually decreased along
with the resolution of the intraretinal cystoid spaces.
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Second is the possibility that RP may also have been a
consequence of chemotherapy, even though we consider
this explanation highly unlikely. We are not aware of
any chemotherapeutical agents proven to be associated
with the development of RP, there is only one case study
reporting acceleration of RP after chemotherapy in a pa-
tient with non-Hodgkin’s lymphoma [15]. As we have no
previous ophthalmological documentation of the patient, it
is not known whether RP existed prior to the chemother-
apy. It is possible that in this case RP has developed due
to a neurotoxic effect of any component of the patient’s
chemotherapeutical regimen. Neurotoxic side effects of
taxanes are frequently recognized, ocular lesions like alter-
ations on the electroretinogram can also occur [16]. The
mechanism of taxanes is to stabilize microtubules to stop
their mitotic activity. This mechanism of action is suggested
to be associated with their neurotoxic side effects as micro-
tubules are responsible for intracellular transport and other
critical cell functions of neurons [17] including photorecep-
tors [18]. In a recent study, it was reported that in RP the
extent of hypoautofluorescent parafoveal arc may corres-
pond with the duration of the disease [19], although pro-
spective longitudinal studies have not confirmed this
observation yet. Unfortunately, we do not have access to
wide-field fundus autofluorescence, thus this second ex-
planation of short-term RP cannot be ruled out this way.
Finally, we cannot exclude another unlikely possibil-
ity that the patient developed CME as a complication
of her RP exclusively. Since CME can occur at any
stage of the disease [4] the association with chemo-
therapy may be coincidental, but the reversibility of
the edema after chemotherapy was stopped suggests
otherwise.
Another important issue to discuss is the termination
of the anti-cancer treatment once an ophthalmic side-
effect occurs. In our case the decision was simple as the
patient underwent complete surgical resection and only
had one cycle of TAC left of her final chemotherapy
treatment. In other cases the ophthalmologist and the
oncologist should weigh the risks and benefits of chemo-
therapy cessation, but the decision should ultimately be
left at the discretion of the oncologist.
Conclusions
In conclusion chemotherapy treatment including doce-
taxel may cause ocular adverse effects such as cystoid
macular edema. Further studies are required to reveal the
possible retinal neurotoxicity of taxanes. It might also be
worthwhile to investigate neuroprotective agents in com-
bination with chemotherapy.
Our observations draw the attention towards possible
ophthalmological side-effects of docetaxel chemother-
apy. It is important for oncologists to advise patients of
the possibility of treatment-related visual complaints and
to report those. Ophthalmic evaluation is warranted to
patients with such complaints.
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